Published in PLoS Curr on August 11, 2011
Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurol (2014) 1.80
WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease. Eur J Hum Genet (2013) 1.07
Onset of Huntington's disease: can it be purely cognitive? Mov Disord (2014) 0.94
HD-PRO-TRIAD™ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease. Tremor Other Hyperkinet Mov (N Y) (2014) 0.81
Everyday cognition in prodromal Huntington disease. Neuropsychology (2014) 0.81
Assessment of Day-to-Day Functioning in Prodromal and Early Huntington Disease. PLoS Curr (2011) 0.80
Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives. Tremor Other Hyperkinet Mov (N Y) (2014) 0.79
Driving with a neurodegenerative disorder: an overview of the current literature. J Neurol (2017) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
Whatever happened to qualitative description? Res Nurs Health (2000) 24.65
Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA (1995) 11.68
Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord (1996) 8.02
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet (2004) 4.73
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol (2009) 3.82
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol (2010) 3.47
Conceptual model of health-related quality of life. J Nurs Scholarsh (2005) 3.10
Huntington's disease: a clinical review. Orphanet J Rare Dis (2010) 2.12
Clinical markers of early disease in persons near onset of Huntington's disease. Neurology (2001) 2.11
"Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci (2010) 1.76
Risk factors for incident mild cognitive impairment--results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). Acta Psychiatr Scand (2009) 1.76
Challenges assessing clinical endpoints in early Huntington disease. Mov Disord (2010) 1.66
Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol (2007) 1.47
Earliest functional declines in Huntington disease. Psychiatry Res (2010) 1.45
Neuro-QOL and the NIH Toolbox: implications for epilepsy. Therapy (2010) 1.04
Capturing the insights of family caregivers: survey item generation with a coupled interview/focus group process. Qual Health Res (2002) 0.90
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry (2007) 2.71
Capacity to provide informed consent for participation in schizophrenia and HIV research. Am J Psychiatry (2002) 2.41
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Neurocognitive signs in prodromal Huntington disease. Neuropsychology (2011) 2.14
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet (2011) 2.05
The value of positron emission tomography in the clinical evaluation of dementia. J Am Geriatr Soc (2003) 2.05
Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ (2009) 2.02
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet (2003) 1.85
Coercion and informed consent in research involving prisoners. Compr Psychiatry (2003) 1.84
Practice effects in the prediction of long-term cognitive outcome in three patient samples: a novel prognostic index. Arch Clin Neuropsychol (2006) 1.77
"Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci (2010) 1.76
Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord (2009) 1.73
An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Mov Disord (2011) 1.68
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain (2007) 1.66
Short-term practice effects in amnestic mild cognitive impairment: implications for diagnosis and treatment. Int Psychogeriatr (2008) 1.64
Measures of growth in children at risk for Huntington disease. Neurology (2012) 1.59
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial. Mov Disord (2012) 1.54
Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry (2010) 1.53
Fully automated analysis using BRAINS: AutoWorkup. Neuroimage (2010) 1.52
Predictors of diagnosis in Huntington disease. Neurology (2007) 1.48
Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol (2007) 1.47
The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry (2003) 1.46
Earliest functional declines in Huntington disease. Psychiatry Res (2010) 1.45
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain (2009) 1.44
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J Int Neuropsychol Soc (2007) 1.38
Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol (2006) 1.36
fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc (2007) 1.35
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain (2010) 1.35
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain (2010) 1.35
White matter volume and cognitive dysfunction in early Huntington's disease. Cogn Behav Neurol (2005) 1.34
Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry (2007) 1.32
Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet (2006) 1.30
Patient and caregiver quality of life in Huntington's disease. Mov Disord (2008) 1.29
Perceptions of discrimination among persons who have undergone predictive testing for Huntington's disease. Am J Med Genet B Neuropsychiatr Genet (2008) 1.29
Factor analysis of the frontal systems behavior scale (FrSBe). Assessment (2003) 1.27
Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics (2004) 1.19
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet (2002) 1.19
Researcher and institutional review board chair perspectives on incidental findings in genomic research. Genet Test Mol Biomarkers (2012) 1.19
Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis (2010) 1.17
Obsessive and compulsive symptoms in prediagnosed Huntington's disease. J Clin Psychiatry (2008) 1.17
Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology (2010) 1.16
Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis (2004) 1.14
Regression-based formulas for predicting change in RBANS subtests with older adults. Arch Clin Neuropsychol (2005) 1.13
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci (2008) 1.12
Probability of obsessive and compulsive symptoms in Huntington's disease. Biol Psychiatry (2006) 1.12
Practice effects predict cognitive outcome in amnestic mild cognitive impairment. Am J Geriatr Psychiatry (2011) 1.11
Estimating premorbid functioning in huntington's disease: the relationship between disease progression and the wide range achievement test reading subtest. Arch Clin Neuropsychol (2010) 1.11
Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci (2013) 1.10
The disclosure of incidental genomic findings: an "ethically important moment" in pediatric research and practice. J Community Genet (2013) 1.10
Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry (2011) 1.09
Experiences of teens living in the shadow of Huntington Disease. J Genet Couns (2008) 1.07
Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Hum Brain Mapp (2012) 1.07
Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry (2012) 1.06
Personal factors associated with reported benefits of Huntington disease family history or genetic testing. Genet Test Mol Biomarkers (2010) 1.06
Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet (2010) 1.05
Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord (2005) 1.05
Blood vessel function and cognition in elderly patients with atherosclerosis. Stroke (2004) 1.05
Neuropsychological performance is associated with vascular function in patients with atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol (2006) 1.05
Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. Eur J Hum Genet (2007) 1.03
The emotional experiences of family carers in Huntington disease. J Adv Nurs (2009) 1.03
VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse (2003) 1.02
Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov Disord (2005) 1.01
8OHdG as a marker for Huntington disease progression. Neurobiol Dis (2012) 1.00
Neurocognitive deficits related to poor decision making in people behind bars. Psychon Bull Rev (2008) 1.00
Predicting cognitive change in older adults: the relative contribution of practice effects. Arch Clin Neuropsychol (2010) 0.99
Tracking motor impairments in the progression of Huntington's disease. Mov Disord (2013) 0.98
The past, present, and future of telemedicine for Parkinson's disease. Mov Disord (2014) 0.97
Multicenter reliability of diffusion tensor imaging. Brain Connect (2012) 0.97
Neuropsychological and psychiatric functioning pre- and posthematopoietic stem cell transplantation in adult cancer patients: a preliminary study. J Int Neuropsychol Soc (2007) 0.96
Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain (2009) 0.96
Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest (2013) 0.95
Classification of neurocognitive disorders in DSM-5: a work in progress. Am J Geriatr Psychiatry (2011) 0.94
Cognitive deficits in Huntington's disease on the Repeatable Battery for the Assessment of Neuropsychological Status. J Clin Exp Neuropsychol (2009) 0.94
Practice effects and outcome of cognitive training: preliminary evidence from a memory training course. Am J Geriatr Psychiatry (2010) 0.93
Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord (2008) 0.93
In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet (2010) 0.93
Association between Age and Striatal Volume Stratified by CAG Repeat Length in Prodromal Huntington Disease. PLoS Curr (2011) 0.92
Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status. J Clin Exp Neuropsychol (2009) 0.92
Development of the Huntington disease family concerns and strategies survey from focus group data. J Nurs Meas (2010) 0.92
Neuropsychological functioning pretreatment and posttreatment in an inpatient eating disorders program. Int J Eat Disord (2003) 0.91
Retrograde amnesia in dementia: comparison of HIV-associated dementia, Alzheimer's disease, and Huntington's disease. Neuropsychology (2004) 0.91
Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol Dis (2010) 0.91
Validity of the 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD). Qual Life Res (2015) 0.91
Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet (2008) 0.91
Diffusion Tensor Imaging in Preclinical Huntington's Disease. Brain Imaging Behav (2009) 0.90
Couples' attributions for work function changes in prodromal Huntington disease. J Genet Couns (2010) 0.90
The Trail Making Test in prodromal Huntington disease: contributions of disease progression to test performance. J Clin Exp Neuropsychol (2011) 0.90
Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease. Arch Clin Neuropsychol (2012) 0.90